{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"elranatamab"},{"type":"USBrandName","name":"Elrexfio"},{"type":"CodeName","name":"PF-06863135"},{"type":"CodeName","name":"PF 06863135"},{"type":"CodeName","name":"PF06863135"},{"type":"Synonym","name":"anti-CD3/anti-BCMA bispecific antibody PF-06863135"},{"type":"Synonym","name":"BCMA x CD3 bispecific antibody PF-06863135"},{"type":"Synonym","name":"BCMA-CD3 bispecific Ab PF-06863135"},{"type":"Synonym","name":"B-cell maturation antigen-CD3 bispecific antibody PF-06863135"},{"type":"CASRegistryName","name":"2408850-14-4"},{"type":"CodeName","name":"RN 613"},{"type":"CodeName","name":"RN-613"},{"type":"CodeName","name":"RN613"}],"definition":{"html":"A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab-bcmm binds to both CD3 on T cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.","text":"A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab-bcmm binds to both CD3 on T cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/elranatamab-bcmm","text":"Elranatamab-bcmm"},"nciConceptId":"C146860","nciConceptName":"Elranatamab","termId":792267,"name":"elranatamab-bcmm","firstLetter":"e","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"elranatamab"}],"links":null}